Status:
COMPLETED
Assessing the Repeatability of NT-proBNP Testing Using Laboratory and Point of Care Testing in PAH
Lead Sponsor:
Sheffield Teaching Hospitals NHS Foundation Trust
Collaborating Sponsors:
Actelion
Conditions:
Pulmonary Artery Hypertension
Eligibility:
All Genders
16+ years
Brief Summary
The purpose of this study is to examine N-terminal pro brain natriuretic peptide (NT-proBNP) and brain natriuretic peptide (BNP) biomarkers in a number of different settings including assessing the re...
Detailed Description
* Patients that are attending clinical appointments will be approached to ask if they will take part in the study. * Patients will be assessed at two separate visits. * Patients will be randomised to ...
Eligibility Criteria
Inclusion
- Patients who have met the criteria for The Sheffield Teaching Hospitals Observational Study of Patients with Pulmonary Hypertension, Cardiovascular and other Respiratory Diseases (STH-ObS)
- Patient diagnosed with Group 1 PAH, including IPAH, HPAH, PAH-CTD but excluding PAH-CHD. Mean pulmonary artery pressure \>20mmHg, PAWP ≤15mmHg and PVR \>240 dynes.
- Willing to participate in the study and able to provide informed consent
Exclusion
- Diagnosed with PAH-CHD or any non-group 1 PH
- Creatinine clearance \< 15 ml/min/m2
Key Trial Info
Start Date :
February 19 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 30 2022
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT05421949
Start Date
February 19 2021
End Date
August 30 2022
Last Update
August 14 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pulmonary Vascular Disease Unit, Royal Hallamshire Hospital
Sheffield, South Yorkshire, United Kingdom, S10 2JF